Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-116 and AMT-253 CAR-T in Advanced Tumors
NCT05117138Phase 2Unknown
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-116, AMT-253 CAR-T cells in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, sponsored by Immunochina Pharmaceuticals. Status: unknown.
02
Drugs
AMT-116AMT-253 CAR-T cells
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)melanoma
Beyond the preview
Go deeper on NCT05117138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117138.